| Inland Physicians Medical Group | |
|
9525 Monte Vista Ave Ste 105 Montclair CA 91763-2231 | |
| (909) 626-1205 | |
| (909) 670-0473 |
| Full Name | Inland Physicians Medical Group |
|---|---|
| Speciality | Internal Medicine |
| Location | 9525 Monte Vista Ave Ste 105, Montclair, California |
| Authorized Official Name and Position | Shahram Khorrami (PARTNER) |
| Authorized Official Contact | 9096261205 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Inland Physicians Medical Group 9525 Monte Vista Ave # 105 Montclair CA 91763-2231 Ph: (909) 626-1205 | Inland Physicians Medical Group 9525 Monte Vista Ave Ste 105 Montclair CA 91763-2231 Ph: (909) 626-1205 |
| NPI Number | 1073632261 |
|---|---|
| Provider Enumeration Date | 03/28/2007 |
| Last Update Date | 08/22/2023 |
| Medicare PECOS PAC ID | 2062406960 |
|---|---|
| Medicare Enrollment ID | O20040413001276 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073632261 | NPI | - | NPPES |
| Provider Name | Elbert Chang |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1053417808 PECOS PAC ID: 7517917958 Enrollment ID: I20050124001105 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Nicolaas Grobler |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1720154255 PECOS PAC ID: 8820160880 Enrollment ID: I20090408000008 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Shahram Khorrami |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1306876123 PECOS PAC ID: 6901963867 Enrollment ID: I20100803001116 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Rick Siriratsivawong |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1669615902 PECOS PAC ID: 9133430275 Enrollment ID: I20150616002615 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Atif Qadeer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1730160201 PECOS PAC ID: 9032188255 Enrollment ID: I20161019000407 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Jose Adriano Santiago |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790763191 PECOS PAC ID: 6800850496 Enrollment ID: I20171019003049 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Ali Salem |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1376983122 PECOS PAC ID: 8729384458 Enrollment ID: I20171024002643 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | John Kim |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1710206024 PECOS PAC ID: 4284913914 Enrollment ID: I20180717004077 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Surbhi Udeshi |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801301718 PECOS PAC ID: 1658615455 Enrollment ID: I20181205001974 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Andres Gonzalez |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1669892147 PECOS PAC ID: 1355693060 Enrollment ID: I20190213002037 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Haaris R Naji |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1023582194 PECOS PAC ID: 1355683012 Enrollment ID: I20190429001165 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Hammad Md Shaikh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1740643063 PECOS PAC ID: 7719216118 Enrollment ID: I20190910003661 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Mohammed Al-khayyat |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1588195424 PECOS PAC ID: 5698048874 Enrollment ID: I20200729002496 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Ramesh Kolli |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1952510091 PECOS PAC ID: 4981790714 Enrollment ID: I20201028002521 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
| Provider Name | Hsin-chen Liu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1609353135 PECOS PAC ID: 5092117176 Enrollment ID: I20210712003708 |
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
News Archive
The brain plays a central role in regulating appetite and whole-body metabolism. A protein known as PPARγ is important in the brain's control of food intake and body weight, but the identity of the neurons regulating this process has been unclear.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
› Verified 5 days ago
Healthcare Services Consulting Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9635 Monte Vista Ave Ste 205, Montclair, CA 91763 Phone: 786-371-4455 | |
All Home Mobile Services Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4795 Holt Blvd Ste 205, Montclair, CA 91763 Phone: 310-507-3280 | |
Khai Do Md Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 9880 Central Ave, Montclair, CA 91763 Phone: 909-621-3012 Fax: 909-621-3015 | |
Kuramed Mobile Group Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4795 Holt Blvd # 210, Montclair, CA 91763 Phone: 909-544-1782 Fax: 909-614-8548 | |
Gb Medical Services Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9670 Central Ave Ste 111, Montclair, CA 91763 Phone: 909-438-8668 | |
Khanh Tan Duong Md Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9635 Monte Vista Ave Ste 208, Montclair, CA 91763 Phone: 909-255-0199 Fax: 216-208-1435 |